Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXHALE-5 long-term open-label dexpramipexole safety study in severe eosinophilic asthma (Japan)
jRCT2031250129Phase 3Completed
- Sponsor
- Areteia Therapeutics, Inc
- Start
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of dexpramipexole in eosinophilic asthma (EA), sponsored by Areteia Therapeutics, Inc. Primary endpoints: Treatment-emergent adverse events, Clinically significant changes in clinical laboratory evaluations and 2 more. Started Jul 2025; status: completed.
02
Drugs
dexpramipexole
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on jRCT2031250129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250129.